Pharminvestor says Paul broke the rules ! I'm sure Paul had both US and Canadian legal counsel
Handle this to be sure it was allowed and done correctly ! There has been plenty of results in the past few years for a big pharma to have a look at ! Pharminvestor has no clue what he is talking about . He is just another alias for WRB who is obsessed and paid to. Bash anything nymox. For the pat several years he has claimed that the P3 trials were a hoax ! Looks like all sellers are done and the stock should move ahead smartly IMO .
passeraser, are you an agent or a promoter for NYMX?
There is no one single peer reviewed publication with NYMX clinical trials data. Therefore, nobody really knows the value (if any) of the drug.
The Ph2 BPH trial results are very old news (5-6 years old). As for the two Ph3 trials, they are double-blind. So, nobody knows the results before the trials are over. The rest is just guesses and speculations. Nobody, based on this info, will put good money on a table.
The Ph2 prostate cancer trial is open-label and half enrolled. So, some results are already available and everybody is ready to see them.
If you have nothing of value to contribute, why don’t you keep your mouth shut?
Pharma, i believe that you are incorrect that no one knows the results before the trial is over. While it is a double blind study, all that means is that no one knows who is in which group and so yo are correct that no one has the real final tabulated data. What you are failing to recognize is that the everyone involved with the trial from the patients to the docs to the nurses and assistants that enter the results into the trial database all have some knowlegde of what kind of results are being seen or not seen in real time. And folks are drawing conclusions and planning longer term based on that. So while a positive result may very well be the result of a placebo effect, you should understand that a number of people are either seeing a marked improvement in a patient or not. Now that's not the same as having all the data, knowing who's in which group and doing the statistical analysis on it, but rest assured a number of folks can see the raw data that is being collected. And you should also rest assured that Dr A and the docs leading the trials have seen the results from the Open Label trial (as well as the raw data from the ongoing Ph3 trials) and are making assessments versus the raw data that is flowing into the blinded trial. And that is helping drive their decision making process in terms of potential deals that may or may not be on the table already.
So anyone would be very mistaken to believe that Dr A is completely blind with regards to the progress/results that are coming in or that he is blindly "rolling the dice" in terms of waiting or not waiting for a deal with terms that make sense. I would strongly argue that the exact oppostive is indeed reality.